Henan University, Kaifeng, Henan, P.R. China.
Department of Neurosurgery, Huaihe Hospital of Henan University, Kaifeng, Henan, P.R. China.
J Cell Mol Med. 2020 Jul;24(13):7538-7549. doi: 10.1111/jcmm.15382. Epub 2020 May 25.
M6A methylation is likely to be closely associated with the occurrence and development of tumours. In this study, we demonstrated that the transcription levels of the m6A RNA methylation regulators are closely related to the prognosis of glioma. Univariate Cox analysis was performed on the expression levels of methylation regulators and selected three hub genes in glioma. Next, we systematically compared the expression of these m6A RNA methylation regulators in gliomas with different clinicopathological features. The overall survival (OS) curve of the hub genes was initially established based on TCGA database information. YTHDF1 was selected from the hub genes following survival and prognosis analysis. A nomogram was developed to predict the survival probability. We further performed cell function and in vivo xenograft tumour experiments to further verify its role in tumour progression. Next, based on the miRanda and miRDB databases, we predicted one microRNA, hsa-mir-346, that might regulate and bind to 3'UTR of YTHDF1, which was confirmed by our fluorescent enzyme reporter gene experiment. In summary, m6A RNA methylation regulators play a potential role in the progression of gliomas. YTHDF1 may have an essential function in glioma diagnosis, treatment and prognosis.
m6A 甲基化可能与肿瘤的发生和发展密切相关。在这项研究中，我们证明了 m6A RNA 甲基化调节剂的转录水平与胶质瘤的预后密切相关。对甲基化调节剂的表达水平进行单因素 Cox 分析，并在胶质瘤中选择了三个枢纽基因。接下来，我们系统地比较了这些 m6A RNA 甲基化调节剂在不同临床病理特征的胶质瘤中的表达情况。根据 TCGA 数据库信息，初步建立了这些枢纽基因的总体生存（OS）曲线。对生存和预后分析后的枢纽基因进行 YTHDF1 选择。开发了一个列线图来预测生存概率。我们进一步进行了细胞功能和体内异种移植肿瘤实验，以进一步验证其在肿瘤进展中的作用。接下来，基于 miRanda 和 miRDB 数据库，我们预测了一个可能调节和结合 YTHDF1 3'UTR 的 microRNA，hsa-mir-346，这一预测通过我们的荧光酶报告基因实验得到了证实。总之，m6A RNA 甲基化调节剂在胶质瘤的进展中发挥了潜在的作用。YTHDF1 可能在胶质瘤的诊断、治疗和预后中具有重要作用。
